Symbols

BIOC(Delisted)

Biocept·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BIOC

Biocept, Inc.

A leading provider of molecular diagnostic assays, products and services

Industry

Established Date

05/12/1997

Listing Date

02/05/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.biocept.com

Security Type

Common stock

Office address

9955 Mesa Rim Road , San Diego , California 92121

Business

Introduction

Biocept, Inc., was founded in California on May 12, 1997. It is a commercial cancer diagnostic company. Research and work on the detection of circulating tumor cells and cancer cells, using a standard blood sample to improve treatment effectiveness, and enabling oncologists to provide patients with more detailed and better information about their cancer cells. The company established the Laboratory, which was accredited by the Clinical Trials Act, passed in 1988, and the American College of Pathology. It produces in-substrate etching microfluidic channels, related equipment and reagents, and then tests them with one of their devices in San Diego. Accreditation and accreditation under the Clinical Experiments Act is a precondition for conducting any human testing in terms of access to diagnostic information, prevention, and disease treatment, or health. The tests they provide are called laboratory-developed diagnostic reagents and comply with the provisions of the Clinical Experiments Act.

Company Financials

EPS

BIOC has released its 2023 Q2 earnings. EPS was reported at -3.5, versus the expected 0, missing expectations. The chart below visualizes how BIOC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BIOC has released its 2023 Q2 earnings report, with revenue of 589.00K, reflecting a YoY change of -89.88%, and net profit of -3.63M, showing a YoY change of 63.85%. The Sankey diagram below clearly presents BIOC's revenue sources and cost distribution.